LLY geopolitical news & exposure

LLY geopolitical news and exposure. LLY appears in 22 Geopolitics Alpha notes. The newest is 02 Oct 2026, 15:20 UTC. Stored price-reaction rows cover 0 of those notes.

• Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s

  02 Oct 2026, 15:20 UTC

• Chief AI officers arrive in C-suites

  02 Oct 2026, 14:39 UTC

• February 2027 Options Now Available For Eli Lilly (LLY)

  02 Oct 2026, 14:34 UTC

• 3 takeaways from a European obesity scientific meeting

  01 Oct 2026, 16:16 UTC

• Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial

  30 Sep 2026, 14:15 UTC

• Here are the 4 big things we're watching in the stock market in the week ahead

  27 Sep 2026, 16:16 UTC

• Amazon, US Steel, Pirelli and others make facility investments, while layoffs progress

  25 Sep 2026, 15:51 UTC

• Novo pursues long-acting obesity drugs; Acadia slumps on Alzheimer’s data

  25 Sep 2026, 13:21 UTC

• Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s

  25 Sep 2026, 11:00 UTC

• Eli Lilly breaks ground on $6.5B Houston manufacturing plant

  24 Sep 2026, 19:51 UTC

• Why we like Starbucks’ latest turnaround move — plus, two more wins for Eli Lilly

  24 Sep 2026, 19:06 UTC

• This GLP-1 drug helped people maintain their weight loss in a clinical trial — even for those taking it once a month

  22 Sep 2026, 15:46 UTC

• An orexin drug’s ‘proof-of-concept’ in ADHD; Cue’s ‘unwarranted’ share slide

  22 Sep 2026, 14:17 UTC

• Eli Lilly CEO offers investors 3 more reasons to stick with the stock

  21 Sep 2026, 23:09 UTC

• Eli Lilly CEO says 700,000 new seniors have started GLP-1s after Medicare coverage, and 70% are on Lilly drugs

  21 Sep 2026, 18:28 UTC

• Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production

  21 Sep 2026, 16:59 UTC

• Novo talks up drug launches in effort to win back investors

  21 Sep 2026, 16:30 UTC

• Novo CEO tells CNBC why drugmaker is rebranding, needs to 'rethink' obesity strategy

  14 Sep 2026, 17:30 UTC

• Novo Nordisk rebrands to 'Novo,' CEO tells CNBC drugmaker needs to 'rethink' strategy amid obesity race

  14 Sep 2026, 15:18 UTC

• Novo Nordisk is changing its name and its culture to try to compete in the GLP-1 diet-drug wars

  14 Sep 2026, 14:05 UTC

• Novo drops ‘Nordisk’ in corporate refresh to take on Lilly in the weight-loss wars

  14 Sep 2026, 13:20 UTC

• Novo Nordisk rebrands to 'Novo,' unveils corporate changes as it fights for obesity market share

  14 Sep 2026, 07:00 UTC